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Abstract
Background: Despite growing concern about illicit methadone use in the US and other countries,
there is little data about the prevalence and correlates of methadone use in large urban areas. We
assessed the prevalence and examined correlates of lifetime and recent illicit methadone use in
New York City (NYC).
Methods: 1,415 heroin, crack, and cocaine users aged 15–40 years were recruited in NYC
between 2000 and 2004 to complete interviewer-administered questionnaires.
Results: In multivariable logistic regression, non-injection drug users who used illicit methadone
were more likely to be heroin dependent, less than daily methamphetamine users and to have a
heroin using sex partner in the last two months. Injection drug users who used illicit methadone
were more likely to use heroin daily, share injection paraphernalia and less likely to have been in a
detoxification program and to have not used marijuana in the last six months.
Conclusion: The results overall suggest that illicit (or street) methadone use is likely not a primary
drug of choice, but is instead more common in concert with other illicit drug use.
Background
Methadone maintenance treatment programs (MMTP)
have been shown to be effective for the management of
opiate addiction, but remain controversial with respect to
placement of clinics [1]. Between 1920 and 1964, physi-
cians who treated substance users with opioids were sub-
ject to prosecution [2]. Among the many concerns of
opponents of MMTPs, the diversion of methadone for
illicit use is a key issue and has been described as "...per-
haps the single greatest threat to the legitimate treatment
of heroin addiction..." [3]. As a result, methadone pro-
grams are highly regulated by the U.S. government and
practitioners are required to register with the U.S. Drug
Enforcement Agency and be accredited by the Substance
Abuse and Mental Health Services Administration [2,4].
In other countries, provision of methadone is not as
restricted. Methadone use is not restricted to the treatment
of heroin dependence, but is also used to manage pain.
There are few studies that have documented the preva-
lence and correlates of illicit methadone use. More than a
decade ago Lauzon and colleagues [5] examined illicit
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Montréal. They found that none reported methadone as
their drug of choice, but the lifetime prevalence of use was
59.4% among those who preferred heroin and 26.7%
among those who preferred cocaine. Mean age of initia-
tion of methadone was older than the mean age of initia-
tion of other substances in this study. More recently, one
study in Australia examined methadone syrup injection
among heroin users [6] and reported a lifetime prevalence
of 18.4%, with 11% reporting use in the last six months
(7.4% used diverted methadone). Methadone syrup injec-
tion was more prevalent among men.
Data about the behavioral correlates of illicit methadone
use are sparse. An early study reported that most illicit
methadone users did not initiate opiate use with metha-
done and that their use was sporadic [7]. More recently, a
Montréal study found that illicit methadone use was more
common about those who used heroin, either alone or in
addition to cocaine, as compared to those who only used
cocaine [5]. An Australian study that examined metha-
done syrup injection found that users were riskier than
those who had not injected methadone; being more likely
to have overdosed, used heroin by themselves and be a
polysubstance user [6].
In the U.S. there has been particular concern about the
increase in prescription drug-related deaths, and thus
many studies assessing the impact of methadone have
focused on methadone-related mortality [c.f., [8-10]].
Several recent studies have looked at overdose deaths and
reported that between 2 and 34% of overdose deaths
either involved methadone or were caused by methadone
[11-14]. Reports have suggested increases in overdose
deaths due to methadone [15,16]. However, few studies
have specifically examined the role of illicit methadone in
fatal overdoses; those that have estimate that between 13
and 57% of methadone-related deaths were due to illicit
methadone [14,17-19]. In New York City (NYC) in partic-
ular, deaths attributable to methadone accounted for 13–
16% of accidental overdose deaths between 1990–1998
[11]. However, this latter study was unable to determine if
the decedents were in MMTP at the time of death or if the
methadone had been illegally obtained. One study found
that mortality related to drug poisoning was significantly
correlated with drug sales for methadone and oxycodone
[20]. In US studies, decedents were generally more likely
to be male [14,18], White [14,18], and older adults
[11,14,18].
Given the concern about illicit methadone use in the US
and other countries and the rate of methadone-related
overdoses in NYC, we sought to extend our previous work
focusing on methadone-related mortality [11]. Here, we
present data on the prevalence and correlates of illicit
methadone use among both injection and non-injection
drug users in NYC. It is the aim of this study to further
understand the epidemiology of illicit methadone use in
the United States. We hypothesized that illicit methadone
use was associated with heroin dependence, and therefore
the prevalence of use among non-injection drug users
(NIDUs) would less than that of injection drug users
(IDUs).
Methods
Subject recruitment
Potential participants were recruited to participate two
ongoing studies of NIDUs and IDUs [21,22] using "street
outreach" techniques, as described elsewhere [23,24].
Briefly, outreach workers engaged drug users in conversa-
tions about ongoing research at the research storefronts or
a mobile van parked in communities where drugs were
bought and/or used. We recruited participants from three
NYC boroughs including: Harlem, the South Bronx, and
the Lower East Side in Manhattan; Jamaica and Queens-
bridge in Queens; and Bedford-Stuyvesant in Brooklyn.
Both IDUs and NIDUs were recruited into two cohort
studies between 2000 and 2004. Potential participants
completed a screening demographic interview. The IDU
study was designed to investigate correlates and predictors
of HIV, hepatitis C virus (HCV), and hepatitis B virus
(HBV) infection and therefore targeted young, recently
initiated IDUs at risk for HCV infection. Participants were
eligible if they were age 15 to 40 years and reported inject-
ing drug use of heroin or cocaine at least once in the last
two months but for no longer than 5 years. The NIDU
study was also designed to investigate correlates and pre-
dictors of HIV, HCV and HBV and recruited young
NIDUs. Participants were eligible if they were age 15 to 40
years and reported non-injecting drug use of heroin or
cocaine at least once per week in the last two months but
for no longer than 10 years, and no history of injecting
drug use. All participants were reimbursed $20 for their
participation. The study was approved by the institutional
review board of the New York Academy of Medicine.
Data collection
Following informed consent, eligible participants com-
pleted a standardized, detailed risk behavior question-
naire administered by trained interviewers. Participants
were asked about sociodemographic characteristics, type
and frequency of drug use, injection drug use practices,
sexual behaviors and sexual partnerships. The absence of
prior drug use by injection was confirmed during the com-
prehensive interviewing process and by phlebotomists'
observations during venipuncture. Street methadone use
was determined by asking, "Have you ever used street
methadone (not from a program)?" and "During the last
6 months, how often did you use street methadone (not
from a program)?"Page 2 of 9
(page number not for citation purposes)
BMC Public Health 2008, 8:375 http://www.biomedcentral.com/1471-2458/8/375Sociodemographic characteristics considered included
age, race, gender, education, recent homelessness, main
income source, and sexual identity. Main income source
was divided into one of four categories: employed (full or
part time employment, self-employed or temporary/off-
books employment), illegal (selling drugs, sex for money,
theft), public assistance (public assistance, welfare, social
security benefits, or state or federal benefits including
food stamps, state public aid, disability, or unemploy-
ment) and other (parent, friend, relative or spouse gave
money; recycling cans; returning bottles for deposits;
windshield wiping; or panhandling for money). Sexual
identity was defined as heterosexual, men who have sex
with men (MSM) and women who have sex with women
(WSW). We examined recent frequency of substance use
in the last six months, focusing on street (illicit) metha-
done, alcohol, marijuana, heroin, crack and cocaine.
Informed consent was obtained in writing from all partic-
ipants.
Statistical methods
We compared sociodemographic characteristics, drug use,
sexual behaviors, and sexual partnerships between those
who had used illicit methadone in the last six months and
those who had not, stratified by injection status. Bivaria-
ble analyses were conducted to assess demographic and
risk behavior variables by recent (last six month) illicit
methadone use using chi-square statistics for categorical
variables and t tests for continuous variables. Covariates
that were significantly associated with recent illicit meth-
adone use in univariable analyses (p < 0.10) were entered
into a multivariable logistic regression model. Only those
variables significant at p < 0.05 were retained in models.
Separate models describing the correlates of street metha-
done use were constructed for injection and non-injection
drug users.
Results
Table 1 presents sociodemographic characteristics of the
samples. Of 955 NIDUs, most were male (69.5%) and
heterosexual (82.3%). Hispanics and Blacks were equally
represented (45.0% and 45.7%, respectively). The mean
age was 30.1 and more than half (57.5%) had recently
been homeless. Of 460 IDUs, most were male (80.4%)
and heterosexual (85.9%). The sample was majority His-
panic (81.1%); only 4.6% were Black. The mean age was
26.4 and most (72.2%) had recently been homeless.
Approximately 21.8% of NIDUs had used illicit metha-
done (also referred to as "street methadone" in local par-
lance) in their lifetime (data not shown) and 11.8% had
used within the last 6 months. In terms of frequency of
use in the last six months, 5.8% used illicit methadone
once or month or less, 1.5% used 2–3 days per month and
3.8% used at least once per week or more (data not
shown). Only 0.9% used on a daily basis. The mean age
of onset for any heroin use was 20.5 years while the age of
onset for illicit methadone was 25.2 years. Of the 208
NIDU lifetime illicit methadone users 9 (4.3%) first used
illicit methadone before they started using heroin, 31
(14.9%) started using illicit methadone and heroin at the
same time, and 159 (76.4%) first used illicit methadone
after they started using heroin. In bivariate analysis (table
1), NIDUs who had recently used illicit methadone were
more likely than non users to be Hispanic [Odds Ratio
(OR) = 1.9, 95% Confidence Interval (CI) = 1.3, 2.9], aged
> 30 (OR = 1.5, 95% CI = 1.0, 2.2), heterosexual (OR =
2.1, 95% CI = 1.1, 4.0), have children (OR = 1.7, 95% CI
= 1.1, 2.6), and been incarcerated (OR = 1.7, 95% CI = 1.0,
2.6). Methadone users were less likely than non users to
be Black (OR = 0.5, 95% CI = 0.3, 0.8) and an MSM (OR
= 0.4, 95% CI = 0.2, 1.0).
Approximately half (52.6%) of the IDU sample had used
illicit methadone in their lifetime (data not shown) and
34.1% had used within the last 6 months. In terms of fre-
quency of use in the last six months, 12.8% used illicit
methadone once a month or less, 6.5% used 2–3 days per
month and 11.3% used at least once per week or more
(data not shown). Only 3.5% used on a daily basis. The
mean age of onset for any heroin use was 19.4 years while
the age of onset for illicit methadone was 23.1 years. Of
the 242 IDU lifetime illicit methadone users 15 (6.2%)
first used illicit methadone before they started using her-
oin, 31 (12.8%) started using illicit methadone and her-
oin at the same time, and 196 (81.0%) first used illicit
methadone after they started using heroin. 165 (68.2%)
initiated illicit methadone and injection at the same age.
There were no significant difference with respect to gen-
der, race, age and sexual orientation among IDUs who
had recently used illicit methadone compared to those
who had not. However, illicit methadone users were less
likely to have public assistance (OR = 0.6, 95% CI = 0.3,
1.1) and more likely to have an illegal source as their main
income source (OR = 1.6, 95% CI = 1.1, 2.4).
In terms of substance use (table 2), NIDU illicit metha-
done users were more likely than non users to be polysub-
stance users (OR = 9.4, 95% CI = 2.3, 38.6), daily heroin
users (OR = 5.1, 95% CI = 3.4, 7.8), less than daily meth-
amphetamine users (OR = 3.5, 95% CI = 1.2, 10.3), her-
oin dependent (OR = 15.3, 95% CI = 8.3, 28.4), and
cocaine dependent (OR = 1.5, 95% CI = 1.0, 2.2). They
were also more likely to have experienced an overdose
(OR = 2.1, 95% CI = 1.2, 3.6) and withdrawal symptoms
(OR = 4.3, 95% CI = 2.8, 6.7) as compared to non users.
NIDU illicit methadone users were also more likely to
have been in a detoxification program (OR = 1.6, 95% CIPage 3 of 9
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6.7, 95% CI = 2.9, 15.7) in the past six months compared
to non users.
IDU illicit methadone users were more likely to be daily
cocaine (OR = 1.7, 95% CI = 1.1, 2.6) and heroin users
(OR = 3.9, 95% CI = 2.4, 6.2), less than daily metham-
phetamine users (OR = 2.8, 95% CI = 0.9, 8.9) and heroin
dependent users (OR = 1.6, 95% CI = 1.5, 1.7). They were
also more likely to have experienced withdrawal symp-
toms (OR = 2.0, 95% CI = 1.3, 3.1) and less likely to have
been in a detoxification program (OR = 0.6, 95% CI = 0.4,
0.9) as compared to non users.
We also examined injection behaviors among the IDU
sample (Table 3). IDU illicit methadone users were signif-
icantly more likely to have injected in a shooting gallery
(OR = 1.8, 95% CI = 1.2, 2.7), rented, borrowed or bought
injection equipment at a shooting gallery (OR = 1.9, 95%
CI = 1.1, 3.3), shared needles (OR 1.5, 95% CI = 1.0, 2.3),
Table 1: Socio-demographics of 1415 drug users, by illicit methadone (IM) use and injection status
Non-injection drug users Injection drug users
Total Current IM use No current IM 
use
Total Current IM use No current IM 
use
n = 955 n = 113 n = 842 n = 460 n = 157 n = 303
n(%)d n(%) n(%) p-valuea n(%)d n(%) n(%) p-valuea
Sex
Male 664 (69.5) 76 (67.3) 588 (69.8) 0.576 370 (80.4) 125 (79.6) 245 (80.9) 0.751
Female 289 (30.3) 37 (32.7) 252 (29.9) 0.541 88 (19.1) 30 (19.1) 58 (19.1) 0.993
Transgender 2 (0.2) 0 (0) 2 (0.2) 1.000b 2 (0.4) 2 (1.3) 0 (0) 0.120b
Race
Hispanic 430 (45.0) 67 (59.3) 363 (43.1) 0.001 373 (81.1) 133 (84.7) 240 (79.2) 0.172
Black 436 (45.7) 36 (31.9) 400 (47.5) 0.002 21 (4.6) 5 (3.2) 16 (5.3) 0.304
White 25 (2.6) 1 (0.9) 24 (2.9) 0.960b 51 (11.1) 16 (10.2) 35 (11.6) 0.651
Other 64 (6.7) 9 (8.0) 55 (6.5) 0.567 14 (3.0) 3 (1.9) 11 (3.6) 0.398b
Mean age (SD)c 30.1 (6.5) 31.8 (6.2) 29.8 (6.5) 0.002 26.4 (5.3) 26.1 (4.9) 26.6 (5.5) 0.388
Sexual 
orientation
Heterosexual 786 (82.3) 100 (88.5) 686 (81.5) 0.033 395 (85.9) 133 (84.7) 262 (86.5) 0.961
MSMe 90 (9.4) 5 (4.4) 85 (10.1) 0.051 13 (8.3) 32 (10.6) 13 (8.3) 0.447
WSWf 102 (10.7) 9 (8.0) 93 (11.0) 0.327 11 (7.0) 21 (6.9) 11 (7.0) 0.955
< High school 
education
526 (55.1) 68 (60.2) 458 (54.4) 0.246 190 (41.3) 67 (42.7) 123 (40.6) 0.709
Homeless in last 
6 months
549 (57.5) 60 (53.1) 489 (58.1) 0.315 332 (72.2) 117 (74.5) 215 (71.0) 0.419
Main source of 
income
Employed 180 (18.8) 18 (15.9) 162 (19.2) 0.334 59 (12.8) 20 (12.7) 39 (12.9) 0.925
Illegal 386 (40.4) 53 (46.9) 333 (39.5) 0.203 254 (55.2) 99 (63.1) 155 (51.2) 0.021
Public Assistance 221 (23.1) 27 (23.9) 194 (23.0) 0.956 65 (14.1) 16 (10.2) 49 (16.2) 0.071
Other 146 (15.3) 15 (13.3) 131 (15.6) 0.459 72 (15.7) 20 (12.7) 52 (17.2) 0.194
Have children 547 (57.3) 77 (68.1) 470 (55.8) 0.013 216 (47.0) 70 (44.6) 146 (48.2) 0.463
Ever been 
incarcerated
661 (69.2) 88 (77.9) 573 (68.1) 0.044 323 (70.2) 112 (71.3) 211 (69.6) 0.632
Site
Bronx 348 (36.4) 43 (38.1) 305 (36.2) 0.704 232 (50.4) 83 (52.9) 149 (49.2) 0.453
Harlem 449 (47.0) 53 (46.9) 396 (47.0) 0.980 171 (37.2) 59 (37.6) 112 (37.0) 0.907
Brooklyn 67 (7.0) 11 (9.7) 56 (6.7) 0.228 22 (4.8) 6 (3.8) 16 (5.3) 0.487
Queens 47 (4.9) 5 (4.4) 42 (5.0) 0.880 6 (1.3) 3 (1.9) 3 (1.0) 0.415
Lower East Side 40 (4.2) 0 (0) 40 (4.8) 1.000b 27 (5.9) 6 (3.8) 21 (6.9) 0.178
HIV+ 101 (10.6) 6 (5.3) 95 (11.3) 0.056 22 (4.8) 6 (3.8) 16 (5.3) 0.457
HBV+ 211 (22.1) 24 (21.2) 187 (22.2) 0.832 141 (30.7) 47 (29.9) 94 (31.0) 0.763
HCV+ 36 (3.8) 6 (5.3) 30 (3.6) 0.247b 255 (55.4) 86 (54.8) 169 (55.8) 0.596
a chi-square unless otherwise indicated
b Fisher's exact test
c ttest
d Column percents may not add up due to missing values
e MSM = men who have sex with men (by behavior or orientation); applies to males only
f WSW = women who have sex with women (by behavior or orientation); applies to females onlyPage 4 of 9
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Non-injection drug users Injection drug users
Total Current IM use No current IM 
use
Total Current IM use No current IM 
use
n = 955 n = 113 n = 842 n = 460 n = 157 n = 303
n(%)d n(%) n(%) p-valuea n(%)d n(%) n(%) p-valuea
Lifetime drug use
Polysubstance usee 831 (87.0) 111 (98.2) 720 (85.5) < 0.001 455 (98.9) 155 (98.7) 300 (99.1) 0.779b
Crack 722 (75.6) 91 (80.5) 631 (74.9) 0.194 383 (83.3) 136 (86.6) 247 (81.5) 0.164
Cocaine 902 (94.5) 107 (94.7) 795 (94.4) 0.906 451 (98.0) 154 (98.1) 297 (98.0) 0.959
Heroin 631 (66.1) 111 (98.2) 520 (61.8) < 0.001 458 (99.6) 157 (100.0) 301 (99.3) 0.549b
Current drug use (in last 6 months)
Crack
None 226 (23.7) 22 (19.5) 204 (24.2) 0.264 84 (18.3) 21 (13.4) 63 (20.8) 0.051
Less than daily 374 (39.2) 50 (44.2) 324 (38.5) 0.238 189 (41.1) 72 (45.9) 117 (38.6) 0.134
Daily 236 (24.7) 25 (22.1) 211 (25.1) 0.497 69 (15.0) 25 (15.9) 44 (14.5) 0.690
Cocaine
None 53 (5.5) 6 (5.3) 47 (5.6) 0.906 27 (5.9) 7 (4.5) 20 (6.6) 0.354
Less than daily 613 (64.2) 72 (63.7) 541 (64.3) 0.911 252 (54.8) 87 (55.4) 165 (54.5) 0.845
Daily 91 (9.5) 14 (12.4) 77 (9.1) 0.270 136 (29.6) 58 (36.9) 78 (25.7) 0.013
Heroin
None 320 (33.5) 1 (0.9) 319 (37.9) < 0.001 4 (0.9) 0 (0) 4 (1.3) 1.000b
Less than daily 354 (37.1) 59 (52.2) 295 (35.0) < 0.001 190 (41.3) 48 (30.6) 142 (46.9) 0.001
Daily 167 (17.5) 51 (45.1) 116 (13.8) < 0.001 303 (65.9) 131 (83.4) 172 (56.8) < 0.001
Methamphetamine
None 892 (93.4) 101 (89.4) 791 (93.9) 0.067 415 (90.2) 137 (87.3) 278 (91.7) 0.098
Less than daily 16 (1.7) 5 (4.4) 11 (1.3) 0.030b 12 (2.6) 7 (4.5) 5 (1.7) 0.073b
Daily 1 (0.1) 0 (0) 1 (0.1) 1.000b 3 (0.7) 0 (0) 3 (1.0) 1.000b
Marijuana
None 163 (17.1) 19 (16.8) 144 (17.1) 0.922 104 (22.6) 23 (14.6) 81 (26.7) 0.003
Less than daily 342 (35.8) 47 (41.6) 295 (35.0) 0.184 187 (40.7) 72 (45.9) 115 (38.0) 0.114
Daily 381 (39.9) 40 (35.4) 341 (40.5) 0.281 148 (32.2) 56 (35.7) 92 (30.4) 0.268
Alcohol
None 133 (13.9) 16 (14.2) 117 (13.9) 0.939 122 (26.5) 37 (23.6) 85 (28.1) 0.301
Less than daily 624 (65.3) 76 (67.3) 548 (65.1) 0.649 294 (63.9) 104 (66.2) 190 (62.7) 0.454
Daily 195 (20.4) 21 (18.6) 174 (20.7) 0.606 44 (9.6) 16 (10.2) 28 (9.2) 0.743
Drug dependence, past year
Heroin dependence 381 (39.9) 97 (85.8) 284 (33.7) < 0.001 421 (91.5) 156 (99.4) 265 (87.5) < 0.001
Crack dependence 509 (53.3) 62 (54.9) 447 (53.1) 0.846 213 (46.3) 77 (49.0) 136 (44.9) 0.595
Cocaine dependence 516 (54.0) 70 (61.9) 446 (53.0) 0.069 308 (67.0) 105 (66.9) 203 (67.0) 0.674
Withdrawal
symptoms in last 6
months
343 (35.9) 72 (63.7) 271 (32.3) < 0.001 276 (60.0) 104 (66.2) 172 (56.8) 0.003
Drug treatment, last 6 months
Detoxification 167 (17.5) 28 (24.8) 139 (16.5) 0.034 171 (37.2) 47 (29.9) 124 (40.9) 0.018
Methadone
maintenance
145 (15.2) 35 (30.1) 110 (13.1) < 0.001 167 (36.3) 120 (39.6) 47 (29.9) 0.942
Medical outcomes
HIV+ 101 (10.6) 6 (5.3) 95 (11.3) 0.056 22 (4.8) 6 (3.8) 16 (5.3) 0.457
HCV+ 36 (3.8) 6 (5.3) 30 (3.6) 0.247b 255 (55.4) 86 (54.8) 169 (55.8) 0.596
HBV+ 211 (22.1) 24 (21.2) 187 (22.2) 0.832 141 (30.7) 47 (29.9) 94 (31.0) 0.763
Overdose 94 (9.8) 19 (16.8) 75 (8.9) 0.008 96 (20.9) 39 (24.8) 57 (18.8) 0.131
Sexual behaviors
Mean age 1st
intercourse (SD)c
14.0 (3.0) 13.9 (3.1) 14.0 (2.9) 0.652 14.1 (2.7) 14.5 (2.4) 13.9 (2.8) 0.020
Mean number of
sexual partners (SD)c
4.8 (14.2) 3.6 (7.5) 4.9 (14.8) 0.144 3.9 (9.8) 4.7 (13.6) 3.4 (6.7) 0.319
Traded sex for
money/drugs
304 (31.8) 32 (28.3) 272 (32.3) 0.389 131 (28.5) 48 (30.6) 83 (27.4) 0.487
Sexual partners in last 2 months
Crack user 354 (37.1) 38 (33.6) 316 (37.5) 0.655 96 (20.9) 32 (20.4) 64 (21.1) 0.818
Cocaine user 323 (33.8) 41 (36.3) 282 (33.5) 0.496 104 (22.6) 41 (26.1) 63 (20.8) 0.239
Heroin use 230 (24.1) 54 (47.8) 176 (20.9) < 0.001 123 (26.7) 47 (29.9) 76 (25.1) 0.247Page 5 of 9
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cottons and rinse water) (OR = 1.6, 95% CI = 1.1, 2.5).
With respect to sexual behaviors and partner characteris-
tics, NIDU illicit methadone users were significantly more
likely to have sexual partners that used heroin (OR = 3.5,
95% CI = 2.3, 5.3), were lifetime (OR = 1.9, 95% CI = 1.1,
3.5) and recent IDUs (OR = 1.9, 95% CI = 1.0, 4.0) and
hepatitis infected (OR = 2.4, 95% CI = 1.1, 5.4). They were
less likely to have an MSM sex partner (OR = 0.7, 95% CI
= 0.4, 1.0). There were no significant differences with
respect to sexual partner characteristics among IDU illicit
methadone users as compared to non users; however, they
had a significantly older mean age at first intercourse
(14.5 years vs. 13.9 years, p = 0.02).
Tables 4 and 5 present the final multivariate logistic
regression models for illicit methadone use among
NIDUs and IDUs, respectively. Recent NIDU illicit meth-
adone users were significantly more likely than non users
to be heroin dependent [Adjusted OR (AOR) = 13.0], less
than daily methamphetamine users (AOR = 5.4), and to
have a heroin using sexual partner in the last six months
(AOR = 2.3). Recent IDU illicit methadone users were sig-
nificantly more likely than non users to be daily heroin
users [Adjusted OR (AOR) = 3.7] and to share cookers,
cotton or rinse water (AOR = 1.6) and significantly less
likely to have been in a detoxification program (AOR =
0.6) and to not have used marijuana in the last six months
(AOR = 0.5).
Discussion
Illicit use of methadone was not uncommon in this pop-
ulation of street-recruited drug users in NYC. Approxi-
mately 21.8% of NIDUs and 52.6% of IDUs in this
sample of street-recruited drug users had used illicit meth-
adone in their lifetime and 11.8 and 34.1% had used
within the last six months, respectively. A previous study
had estimated a 21.3% past month prevalence for illicit
methadone among Puerto Rican IDUs in East Harlem,
New York [25]. In Australia, the lifetime and six month
prevalence of injected methadone was 18.4% and 11.0%,
respectively [6]. Our data did not distinguish between
route of administration and the Australian study did not
report on non-injected illicit methadone use, thus com-
parison between the estimates is limited. In Montréal, the
illicit methadone prevalence was 42.1% among those
who preferred heroin [5]. Although we did not ask about
drug preference, frequency of use can serve as a proxy
measure. Among the NIDUs and IDUs, approximately
38.7% of daily heroin users and 19.7% of less than daily
heroin users also used illicit methadone. Differences in
the prevalence of illicit methadone use among these stud-
ies are probably due, in part, to differences in sampling
schemes and differences in measurement. However,
methadone prescribing policies differ between countries
and also play an important role in MMTP and illicit meth-
adone availability.
Our study revealed that illicit methadone users engaged in
riskier behavior than those who did not use street metha-
done, as evidenced by the higher prevalence of overdose
experiences, polysubstance use and risky sex partners
among NIDU illicit methadone users. Humeniuk and col-
leagues have suggested that methadone injectors are risk-
ier than those who do not inject methadone, with
methadone injectors in their population being more
likely to have overdosed, used heroin by themselves and
be a polysubstance user [6]. Further, we observed that
IDUs who used street methadone reported riskier injec-
Lifetime IDU 81 (8.5) 16 (14.2) 65 (7.7) 0.034 122 (26.5) 39 (24.8) 83 (27.4) 0.576
Recent IDU 50 (5.2) 10 (8.8) 40 (4.8) 0.069 110 (23.9) 36 (22.9) 74 (24.4) 0.693
Partner MSMf 388 (40.6) 36 (31.9) 352 (41.8) 0.061 156 (33.9) 51 (32.5) 105 (34.7) 0.573
Hepatitis infected 34 (3.6) 8 (7.1) 26 (3.1) 0.040b 38 (8.3) 12 (7.6) 26 (8.6) 0.639
HIV infected 47 (4.9) 3 (2.7) 44 (5.2) 0.930b 9 (2.0) 4 (2.5) 5 (1.7) 0.385b
a chi-square unless otherwise indicated, b Fisher's exact test, c ttest, d Column percents may not add up due to missing values, e used more than one 
drug out of the following in lifetime: heroin, crack, cocaine, methamphetamine, f MSM = men who have sex with men
Table 2: Drug use and sexual behaviors of 1415 drug users by illicit methadone (IM) use and injection status (Continued)
Table 3: Injection risk behaviors of 460 IDUs in New York City by recent illicit methadone use
Illicit methadone use
Total Current use No current use
n = 460 n = 157 n = 303
n(%)d n(%) n(%) p-value
Shot up in a shooting gallery 150 (32.6) 65 (41.4) 85 (28.1) 0.005
Used equipment at shooting gallery (rented/borrowed/bought) 94 (20.4) 47 (29.9) 47 (15.5) 0.027
Shared tourniquet 155 (33.7) 60 (38.2) 95 (31.4) 0.249
Shared cooker, cotton, or rinse water 292 (63.5) 111 (70.7) 181 (59.7) 0.021
Shared needles 193 (42.0) 76 (48.4) 117 (38.6) 0.033Page 6 of 9
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they were more likely to attend a shooting gallery and
buy, rent or borrow injection equipment at a shooting gal-
lery as well as share needles and other injection parapher-
nalia (i.e. cookers, cotton and rinse water). This is a novel
finding. Hopwood and colleagues reported that metha-
done syrup injecting in New South Wales was not associ-
ated with sharing injection equipment, but it was
associated with reuse of methadone injecting equipment
[26].
Predictably, recent illicit methadone use was associated
with heroin dependence among NIDUs and daily heroin
use among IDUs. It is likely that dependence and daily use
are measuring the same underlying construct of severity of
use. Coupled with the data demonstrating relatively low
frequency of use and later age of onset as compared to
other both heroin and injection drug use, these findings
suggest that illicit methadone use is likely not a primary
drug of choice. This finding parallels that of Lauzon and
colleagues in Montréal [5], who reported a later age of
onset for illicit methadone use as compared to heroin,
cocaine and a variety of other substances. The association
between heroin dependence, daily heroin use and illicit
methadone use suggests that methadone is used ancillary
to heroin.
In the multivariate model for NIDUs, having a heroin
using partner in the last two months was associated a
more than two-fold increase in the likelihood of illicit
methadone use. One possible explanation is that the sex
partners are also drug use partners, pooling resources to
purchase drugs. This would then suggest that having a her-
oin using sex partner may be related to more severe heroin
use. Less than daily methamphetamine use was associated
with a more than five-fold increase in the likelihood of
illicit methadone use. Considering the low prevalence of
methamphetamine use in this population, this associa-
tion may be spurious. Little is known about methamphet-
amine use in NYC, although several recent studies have
examined its use among gay and bisexual men [27-29].
These findings need further exploration.
Illicit methadone use among IDUs was associated with a
significant increase in the likelihood of sharing injection
paraphernalia such as cookers, cottons and rinse water,
even after adjusting for daily heroin use, suggesting that
street methadone use may be part of a larger profile of
risky drug use behavior. Surprisingly, IDU illicit metha-
done users had a significantly lower likelihood of recent
detoxification treatment compared to non users. One pos-
sible explanation is that detoxification may be perceived
as ineffective or undesirable to chronic heroin users.
Another explanation may be that IDUs are using street
methadone to detox themselves.
As with any study, this study is subject to several limita-
tions. The study sample was limited to users of heroin,
crack and cocaine and specifically recent initiates to injec-
tion drug users and those who had never injected drugs.
Other groups that may use illicit methadone including
former and current pain patients, individuals who abuse
prescription opioids, youth and other populations were
not included. Correlates of illicit methadone use among
those who are not heroin users and among those whose
drug of choice is methadone are likely different. Further,
the extent to which these findings are generalizable to
other settings with different demographic profiles is
unknown. Our population was relatively young and had
few White drug users and Black injectors.
Table 4: Multivariate logistic regression model for recent illegal methadone use among 955 non-injection drug users
Crude OR Adjusted OR
(95% CI) (95% CI)
Heroin Dependence 15.3 (8.3, 28.4) 13.0 (6.8, 25.0)
Current user of methamphetamines: less than daily 3.5 (1.2, 10.3) 5.4 (1.4, 20.1)
Sexual partner used heroin in last 2 months 3.5 (2.3, 5.3) 2.3 (1.4, 3.6)
Table 5: Multivariate logistic regression model for recent illegal methadone use among 955 injection drug users
Crude OR Adjusted OR
In the last 6 months... (95% CI) (95% CI)
Daily heroin use 3.8 (2.4, 6.2) 3.7 (2.3, 6.1)
Detoxification program 0.6 (0.4, 0.9) 0.6 (0.4, 0.9)
Shared cookers, cotton or rinse water 1.6 (1.1, 2.5) 1.6 (1.0, 2.4)
No marijuana use 0.4 (0.3, 0.8) 0.5 (0.3, 0.9)Page 7 of 9
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region and the extent to which heroin is a primary drug of
choice can vary widely [30,31]. Opioid analgesic sales per
100,000 population also vary widely by state [20]. Bour-
gois [32] has pointed out that methadone prescribing phi-
losophies can differ between cities such that availability of
methadone may be different between cities. We did not
have data on route of administration of street methadone
and therefore cannot look specifically at methadone injec-
tion. We do not think that injection is a common route of
administration; Humeniuk et al. [6] reported that less
than 20% in a study of heroin users in Australia reported
lifetime methadone injection.
These data do not provide a complete picture of illicit
methadone use and thus are limited. Two important ques-
tions remain unanswered. First, the reasons for illicit
methadone use were not investigated. There are several
possible reasons that individuals may use illicit metha-
done, including unavailability of heroin, underdosing in
methadone programs and/or pain management, and
experimentation prior to entry into a methadone pro-
gram. In Australia, one study reported that 58% of meth-
adone injectors preferred injection because it provided
quicker relief of opiate withdrawal symptoms than drink-
ing the syrup [26], suggesting that underdosing may be an
important consideration. A study of U.S. methadone
maintenance facilities found that approximately one-
third provided dose under the recommended level [33].
Some proportion of illicit methadone use might then be
attributed to attempts at self-medication either by supple-
menting MMTP, reducing dependence on heroin without
the use of a formal treatment program, or preventing
withdrawal symptoms when heroin is otherwise not avail-
able as has been suggested in earlier studies [7,34]. A
recent study of patients in a German detoxification ward
reported that approximately one-third reported using
diverted opiods as an attempt at self-detoxification, when
a dose of prescribed methadone had been missed, or as a
transition before entering methadone maintenance treat-
ment [35]. It has also been suggested that low availability
of methadone treatment slots may be an important factor
in the creation of an illicit street-level market for metha-
done [5]. Although bivariate analyses demonstrated a
relationship between MMTP and illicit methadone use
among NIDUs, this association was not significant in the
multivariate analysis. Only 30.4% of illicit methadone
users were recently in MMTP, suggesting that illicit meth-
adone use may not simply be a result of underdosing of
MMTP patients or personal diversion of medication. From
these data, it is unclear if the remaining 67.6% of illicit
methadone users are former MMTP patients. Second, the
illicit methadone sources of participants in this study
remain unknown. Several avenues for acquisition are
likely available, including methadone available due to
theft from hospitals or pharmacies, diversion from main-
tenance programs, or diversion from pain management
prescriptions.
Conclusion
Despite these limitations, this study suggests that persons
using illicit methadone use are likely to be heavily risk
prone (i.e., heavy users and those who report high risk
behaviors). Further studies can clarify the mechanisms
that may lead to more refined approaches to respond to
this treatment problem. Additional qualitative and quan-
titative research is needed to understand the context of
illicit methadone use and potential targets for interven-
tion.
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